Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Shi, Sen; Koya, Daisuke; Kanasaki, Keizo
• Is Part Of: Fibrogenesis & tissue repair. Volume 9:Issue 1(2016)
• Page Start: 1
• Page End: 10
• Publication Date: 2016-12
• Subjects: Diabetic nephropathy -- Dipeptidyl peptidase-4 -- Kidney protection; Fibrosis -- Periodicals; Wound healing -- Periodicals; Regeneration (Biology) -- Periodicals; 617.1
• DOI: 10.1186/s13069-016-0038-0
• Languages: English
• ISSNs: 1755-1536

Abstract

Abstract Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the DPP-4 activity is the highest level per organ weight. A preclinical analysis revealed that DPP-4 inhibitors also ameliorated kidney fibrosis. In this review, we analyzed recent reports in this field and explore the renoprotective effects and possible mechanism of the DPP-4 inhibitors.